Rigel Pharmaceuticals Return On Asset vs. Current Valuation
RIGL Stock | USD 20.56 2.60 11.23% |
For Rigel Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rigel Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rigel Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rigel Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rigel Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rigel |
Rigel Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.27 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Rigel Pharmaceuticals Current Valuation vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rigel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rigel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Rigel Pharmaceuticals is currently regarded as top stock in return on asset category among its peers. It is rated fifth in current valuation category among its peers reporting about 7,836,859,479 of Current Valuation per Return On Asset. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rigel Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Rigel Current Valuation vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Rigel Pharmaceuticals |
| = | 0.0461 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Rigel Pharmaceuticals |
| = | 361.28 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Rigel Current Valuation vs Competition
Rigel Pharmaceuticals is rated fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 4.62 Billion. Rigel Pharmaceuticals holds roughly 361.28 Million in current valuation claiming about 8% of equities under Health Care industry.
Rigel Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rigel Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rigel Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Rigel Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Rigel Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | 8 K | 8.4 K | |
Operating Income | -20.5 M | -21.5 M | |
Net Loss | -25.1 M | -26.3 M | |
Income Tax Expense | 2.3 M | 2.4 M | |
Income Before Tax | -25.1 M | -26.3 M | |
Total Other Income Expense Net | -4.6 M | -4.4 M | |
Net Loss | -67.4 M | -70.7 M | |
Net Loss | -24.4 M | -25.6 M | |
Non Operating Income Net Other | 786.6 K | 936.5 K | |
Interest Income | 2 M | 1.2 M | |
Net Interest Income | -4 M | -3.8 M | |
Change To Netincome | 11.8 M | 7.6 M | |
Net Loss | (1.44) | (1.51) | |
Income Quality | 0.23 | 0.22 | |
Net Income Per E B T | 0.95 | 0.82 |
Rigel Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rigel Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rigel Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rigel Pharmaceuticals' important profitability drivers and their relationship over time.
Use Rigel Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rigel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rigel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Rigel Pharmaceuticals Pair Trading
Rigel Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Rigel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rigel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rigel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rigel Pharmaceuticals to buy it.
The correlation of Rigel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rigel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rigel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rigel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Rigel Pharmaceuticals position
In addition to having Rigel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Volatility ETFs Thematic Idea Now
Volatility ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Check out Your Equity Center. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
To fully project Rigel Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rigel Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rigel Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.